Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Conversion From Immediate Release Tacrolimus to Envarsus XR® in Simultaneous Pancreas-Kidney Recipients: Assessment of Functional, Safety and Quality of Life Outcomes (CIRTEN SPK)

Trial Profile

Conversion From Immediate Release Tacrolimus to Envarsus XR® in Simultaneous Pancreas-Kidney Recipients: Assessment of Functional, Safety and Quality of Life Outcomes (CIRTEN SPK)

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 12 Feb 2019

At a glance

  • Drugs Tacrolimus (Primary)
  • Indications Kidney-pancreas transplant rejection
  • Focus Adverse reactions
  • Acronyms CIRTEN SPK
  • Most Recent Events

    • 08 Feb 2019 Planned initiation date changed from 1 Feb 2019 to 15 Feb 2019.
    • 01 Feb 2019 Planned initiation date changed from 21 Jan 2019 to 1 Feb 2019.
    • 01 Feb 2019 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top